RxDoctor Payments Data

Rumman Syed, MD

Cardiovascular Disease · Lebanon, NHNPI 1669995841

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,772 of the $9,490 with a category attached, or 71.4%. It is spread thinly across 27 manufacturers, the largest accounting for just 19.0%. 2025 is the largest year on record at $3,987, more than ten times the $13 reported in 2019.

$9,490in general payments, 2019–2025

Across 127 payments — averaging $74.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Johnson & Johnson$1K
  • Medtronic$1K
  • Abbott$849
  • W. L. Gore & Associates, Inc.$688
  • Shockwave Medical, Inc$579
  • plus $3K from 21 others

What the payments were for

  • Travel & lodging$2,13222%
  • Food & beverage$6,77271%
  • Education$5866%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,490 in reported general payments places this provider in the 85th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$2,690
Medicare patients
18
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin11$6,117
ClopidogrelClopidogrel Bisulfate27$327
Metoprolol Succinate13$124

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →